Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
Cefquinome sulphate
LIVISTO Int'l, S.L.
QJ51DE90
Cefquinome sulphate
75 mg/syringe
Intramammary ointment
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle
cefquinome
Antibacterial
Authorised
2018-06-01
Health Products Regulatory Authority 07 June 2018 CRN000V32 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Qivitan LC 75 mg intramammary ointment for lactating cows 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prefilled syringe of 8 g contains: ACTIVE SUBSTANCE: Cefquinome 75 mg (as cefquinome sulfate 88.92 mg) EXCIPIENTS: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Intramammary ointment White to slightly yellow, oily viscous homogeneous ointment. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (lactating cows). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of clinical mastitis in the lactating cow caused by the following cefquinome-sensitive organisms: _Streptococcus uberis, Streptococcus dysgalactiae, _ _Staphylococcus aureus_ and_ Escherichia coli_. 4.3 CONTRAINDICATIONS Do not use in known cases of hypersensitivity to cephalosporin antibiotics, other ß-lactam antibiotics or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Health Products Regulatory Authority 07 June 2018 CRN000V32 Page 2 of 6 4.5 SPECIAL PRECAUTIONS FOR USE i. Special precautions for use in animals The product should be reserved for the treatment of clinical conditions which have responded poorly or are expected to respond poorly to other classes of antimicrobials or narrow spectrum β-lactam antimicrobials. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If it is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the product is used. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefquinome and may decrease the effectiveness of treatment with cephalosporins due to the potential for cross-resistance. The feedi Leggi il documento completo